BlackRock raises stake in Hengrui Medicine H-shares to 7.05%
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
According to information from the Hong Kong Stock Exchange, BlackRock, the world's largest asset manager, increased its shareholding in Hengrui Medicine's H-shares from 6.99% to 7.05% on September 16. The disclosure, reported by Chinese financial media outlet Cailianshe on September 21, indicates a marginal increase in BlackRock's position in the Chinese pharmaceutical company. This filing provides a snapshot of institutional investor activity in the Hong Kong-listed shares of Hengrui Medicine, a major Chinese drugmaker. The change in stake, while small, reflects ongoing portfolio adjustments by a major global investment firm in the Chinese healthcare sector.
Source report
Date: September 21 (Cailianshe)
According to disclosures from the Hong Kong Stock Exchange, BlackRock's shareholding in Hengrui Medicine's H-shares rose from 6.99% to 7.05% on September 16.
Source
财联社Eastern
Part of this Story
BlackRock adjusts stakes in multiple Chinese H-shares, reducing Haier and CATL positions